ライフサイエンスコーパス: PDE5 inhibitor

1 inhibited (IC50 = 35 microM) by zaprinast, a PDE5 inhibitor.

2 postinil, inorganic nitrate (NO donor), or a PDE5 inhibitor.

3 ter sun exposure among patients exposed to a PDE5 inhibitor.

4 s have been prepared as potent and selective PDE5 inhibitors.

5 discovered as extremely potent and selective PDE5 inhibitors.

6 ts of long-term treatments with low doses of PDE5 inhibitors.

7 a novel series of aminopyridopyrazinones as PDE5 inhibitors.

8 hypertrophic and cardioprotective effects of PDE5 inhibitors.

9 y sildenafil, a popular phosphodiesterase 5 (PDE5) inhibitor.

10 nduction are blocked by phosphodiesterase 5 (PDE5) inhibitors.

11 ent animal and human data support the use of PDE5 inhibitor and the generation of early erections aft

12 imal and human studies imply that the use of PDE5 inhibitor and the generation of erections early aft

13 Ever use of a PDE5 inhibitor and time-updated cumulative number of PDE

14 All men initiating a PDE5 inhibitor and with no prior cancer diagnosis were i

15 Further, the combination of PDE5 inhibitors and agents that increase cGMP or cAMP al

16 Combination of PDE5 inhibitors and alpha1-adrenergic blockers may have

17 Combination therapy using PDE5 inhibitors and alpha1-adrenergic blockers resulted

18 Treatment with PDE5 inhibitors and chemotherapy drugs promoted autophag

19 Phosphodiesterase-5 (PDE5) inhibitors and other agents that modulate intracel

20 erized bovine hemoglobin (HBOC), sildenafil (PDE5 inhibitor), and lactated Ringer's solution (control

21 and is additive with prostacyclin analogues, PDE5 inhibitor, and NO.

22 Because PDE5 inhibitors are currently used as therapeutic agents

23 Recent studies have shown that PDE5 inhibitors are potent acute pulmonary vasodilators

24 Given that side effects of PDE5 inhibitors are widely known and do not preclude the

25 ates, and may ultimately provide a basis for PDE5 inhibitors as a treatment for pulmonary hypertensio

26 dings demonstrate a potentially novel use of PDE5 inhibitors as adjuncts to tumor-specific immune the

27 We report the use of PDE5 inhibitors as modulators of the antitumor immune re

28 , 435 men (11%) had filled prescriptions for PDE5 inhibitors, as did 1713 men of 20,325 controls (8%)

29 The PDE5 inhibitors augment the antithrombotic effects of ni

30 The PDE5 inhibitors augment the blood pressure (BP)-lowering

31 Our results were not consistent with PDE5 inhibitors being causally associated with melanoma

32 It is recognized that PDE5 inhibitors can have cardioprotective effects in oth

33 fil citrate (Viagra), a phosphodiesterase 5 (PDE5) inhibitor, can be used to ameliorate the age-relat

34 ion recapitulated the combination effects of PDE5 inhibitor drugs with chemotherapy drugs.

35 PDE5 inhibitors (eg, sildenafil) are licensed for PH, bu

36 PDE5 inhibitors enhanced and prolonged the induction of

37 research, highlight the potential utility of PDE5 inhibitors for ameliorating emotion recognition def

38 This article focuses on the use of PDE5 inhibitors for BPH/LUTS treatment and highlights th

39 importance of sex differences in the use of PDE5 inhibitors for treating heart disease and the criti

40 Men taking PDE5 inhibitors had a higher educational level and annua

41 Recently, PDE5 inhibitors have been found to regulate smooth muscl

42 Phosphodiesterase-5 (PDE5) inhibitors improve exercise capacity and quality o

43 especially after the therapeutic success of PDE5 inhibitors in the treatment of erectile dysfunction

44 e safety, efficacy and cost-effectiveness of PDE5 inhibitors in the treatment of LUTS secondary to BP

45 hich are both more potent and more selective PDE5 inhibitors in vitro than sildenafil.

46 dition of sildenafil, a phosphodiesterase 5 (PDE5) inhibitor, in the drinking water had a small effec

47 Phosphodiesterase-5 (PDE5) inhibitors increase intracellular concentrations o

48 tumor cells expressing mutant active K-RAS, PDE5 inhibitors interacted in a greater than additive fa

49 onal status, at clinically achievable doses, PDE5 inhibitors interacted in a greater than additive fa

50 her clinically relevant phosphodiesterase 5 (PDE5) inhibitors interacted with clinically relevant che

51 , NY), a selective phosphodiesterase type-5 (PDE5) inhibitor, is widely used to treat impotence by im

52 dysfunction drugs, phosphodiesterase type 5 (PDE5) inhibitors, is part of a pathway implicated in the

53 Vardenafil, a potent PDE5 inhibitor (K(i) = 0.2 nM), was the most potent PDE6

54 Phosphodiesterase 5 (PDE5) inhibitors limit myocardial injury caused by stres

55 As well, chronic administration of PDE5 inhibitors may also help maintain the smooth muscle

56 Overall, the data suggest that PDE5 inhibitors may be a useful treatment for the cardio

57 tudies have provided promising evidence that PDE5 inhibitors may be an effective and well tolerated t

58 it appears from recent clinical studies that PDE5 inhibitors may increase the risk of malignant melan

59 or the combination of inhaled NO with either PDE5 inhibitor (n = 4 per group).

60 The present study tested PDE5 inhibitors on the cGMP-mediated modulation of K(+)

61 g critical insights into the side effects of PDE5 inhibitors on vision.

62 effects of tadalafil (Cialis), a long acting PDE5 inhibitor, on brain cGMP levels, neurogenesis, angi

63 t of Sildenafil, a phosphodiesterase type 5 (PDE5) inhibitor, on nestin lineage neural stem cells and

64 a highly-specific type 5 phosphodiesterase (PDE5) inhibitor, on platelet-mediated cyclic coronary fl

65 nt and highly selective phosphodiesterase-5 (PDE5) inhibitor, on symptom-limited exercise time, time

66 aimed to assess the effects of tadalafil--a PDE5 inhibitor--on exercise capacity and quality of life

67 an increased risk of melanoma in men taking PDE5 inhibitors (OR, 1.21 [95% CI, 1.08-1.36]).

68 eclinical and experimental studies show that PDE5 inhibitors (PDE5is) exert protective effects in DN

69 e previously reported potent quinoline-based PDE5 inhibitors (PDE5Is) for the treatment of Alzheimer'

70 nclusion, the safety and efficacy profile of PDE5 inhibitor PF-00489791 supports further investigatio

71 the novel, highly specific, and long-acting PDE5 inhibitor, PF-00489791, was assessed in a multinati

72 The PDE5 inhibitors potentiated the antithrombotic propertie

73 145,104 men with >/=1 PDE5 inhibitor prescription, and 560,933 unexposed match

74 ibitor and time-updated cumulative number of PDE5 inhibitor prescriptions were investigated as exposu

75 Phosphodiesterase-5 (PDE5) inhibitors promote nitric oxide activity and enhan

76 Sildenafil (Viagra), a specific PDE5 inhibitor, promotes penile erection by blocking the

77 ata demonstrates that oral administration of PDE5 inhibitors selectively increases BTB permeability a

78 mising results in males, the efficacy of the PDE5 inhibitor sildenafil in female cardiac pathologies

79 d in vivo, but it has been proposed that the PDE5 inhibitor sildenafil is prothrombotic.

80 Number of filled prescriptions for the PDE5 inhibitors sildenafil and vardenafil or tadalafil.

81 udies indicate that the phosphodiesterase 5 (PDE5) inhibitor sildenafil is protective against hypertr

82 Surprisingly, the phosphodiesterase 5 (PDE5) inhibitor sildenafil was found to possess submicro

83 To determine whether the PDE5-inhibitor sildenafil benefits human dystrophinopath

84 ly overcome by combing HBOC treatment with a PDE5 inhibitor (sildenafil).

85 PDE5 inhibitors (sildenafil, tadalafil, vardenafil, etc.

86 on of nNOS effects by a phosphodiesterase 5 (PDE5) inhibitor (sildenafil) improves skeletal and cardi

87 Phosphodiesterase-5 (PDE5) inhibitors (sildenafil, tadalafil, and vardenafil)

88 butyl-1-methyl-xanthine or the new selective PDE5 inhibitor, sildenafil, but it is inhibited by the P

89 ddition, treatment of mdx(5cv) mice with the PDE5 inhibitor, sildenafil, which was one of the six dru

90 5 in median inhibitory concentration for the PDE5 inhibitors, sildenafil, or zaprinast 3-isobutyl-1-m

91 In the present study, sildenafil, like other PDE5 inhibitors, stimulates cGMP binding to the alloster

92 t and selective pyrimidinyl pyrroloquinolone PDE5 inhibitors such as 2a for potential use in male ere

93 nic treatment of pulmonary hypertension with PDE5 inhibitors such as sildenafil.

94 PDE5 inhibitors such as Viagra block the activity of suP

95 n follow-on experiments the influence of the PDE5 inhibitor tadalafil on the development of doxorubic

96 Similar to other PDE5 inhibitors, tadalafil should not be administered in

97 azoquinazolinone nucleus as a more selective PDE5 inhibitor template compared to the pyrazolopyrimidi

98 en identified as a more potent and selective PDE5 inhibitor than sildenafil (1).

99 otide field that culminated in the advent of PDE5 inhibitors that treat erectile dysfunction, such as

100 larities with PDE5, we utilized radiolabeled PDE5 inhibitors to probe the catalytic sites of PDE6.

101 e has been increasing interest in the use of PDE5 inhibitors to treat BPH/LUTS.

102 ate the ability of type 5 phosphodiesterase (PDE5) inhibitors to augment the antithrombotic effects o

103 This study compared adding sildenafil, a PDE5 inhibitor, to conventional treatment with the curre

104 continued investigation of combined HBOC and PDE5 inhibitor treatment in circumstances in which HBOC

105 t solar keratosis was associated with future PDE5 inhibitor use (odds ratio = 1.28, 95% CI 1.23-1.34,

106 ence of a small positive association between PDE5 inhibitor use and melanoma risk (HR = 1.14, 95% CI

107 We therefore aimed to investigate whether PDE5 inhibitor use is associated with an increased risk

108 PDE5 inhibitor use was also associated with an increased

109 gher sun exposure were more likely to become PDE5 inhibitor users.

110 The most potent PDE5 inhibitor was sildenafil.

111 In a Swedish cohort of men, the use of PDE5 inhibitors was associated with a modest but statist

112 yl pyrroloquinolones as potent and selective PDE5 inhibitors was reported.

113 PDE5 inhibitors were significantly associated with melan

114 device therapy, dietary supplementation and PDE5 inhibitors which is described in detail.

115 This paper describes the discovery of 14, a PDE5 inhibitor with improved potency and selectivity in

116 our data demonstrate that the combination of PDE5 inhibitors with standard of care chemotherapy agent

117 ction with tadalafil, a phosphodiesterase 5 (PDE5) inhibitor with a half-life (t(1/2)) of 17.5 h.

118 nafil, a type 5 phosphodiesterase isoenzyme (PDE5) inhibitor with a short half-life, increases brain

119 Phosphodiesterase type 5 (PDE5) inhibitors with improved PDE isozyme selectivity r

120 In addition, studies on animals reveal that PDE5 inhibitors work in concert with nitric oxide and/or

121 -polymerized bovine hemoglobin (HBOC) with a PDE5 inhibitor would counter the negative hemodynamic co

122 This activity was inhibited by the selective PDE5 inhibitors zaprinast and DMPPO.